WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

News

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately held rare disease company, announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Steven Singer and Gary Schall led WilmerHale's representation of Vtesse in this transaction, with a team that included Steven Barrett, William Caporizzo, Jeffrey Hermanson, Scott Kilgore, David Sluis, Libby Ragan, Ben Kelsey and Alan Wilson.

View Vtesse's press release for details.